Immune Checkpoint Inhibitors – Special Topics – Special Topics: Immune Checkpoint Inhibitors (G7)

Immune checkpoint inhibitors have had a transformative impact in many oncology settings since their entry into the marketplace a little over a decade ago. Their use continues to advance into earlier lines of therapy, including the adjuvant and neoadjuvant settings, and into novel combinations with both existing and emerging agents. Combinations of PD-1 / PD-L1 checkpoint inhibitors with therapies targeting other immune checkpoints, such as LAG-3, also feature in approved and emerging regimens. This Special Topics report gives a comprehensive market forecast of current and emerging immune checkpoint inhibitors and their market trends and dynamics in a variety of oncology indications.


  • What are the approval timelines and current landscapes for approved immune checkpoint inhibitors, and what combination strategies are being more successful?
  • What is the market potential and positioning of emerging immune checkpoint inhibitors?
  • What is the commercial potential of current and emerging immune checkpoint inhibitors by brand, indication, combination, and geography, and how will the market evolve over the 2022-2032 forecast period?


United States, EU5, Japan.


Drug-treated cases by brand, indication, combination type, and geography for indications for which immune checkpoint inhibitors are approved or forecast for approval.


10-year, annualized, drug-level sales of immune checkpoint inhibitors through 2032, segmented by indication, target, combination type, and geography.


Currently approved agents targeting PD-1, PD-L1, CTLA-4, and LAG-3.


Phase 3 / PR.


Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the immune checkpoint inhibitor landscape in relevant oncology indications.